Skip to main content

Table 1 Patient Characteristics

From: Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Patient Characteristics N (%)
Age (years), Median (range) 53 (39–76)
Sex
 Male 5 (63)
 Female 3 (37)
Race
 White 7 (88)
 Black 1 (12)
Histology
 Thymoma 7 (88)
 B1 1
 B2 3
 B3 3
 Thymic carcinoma 1 (12)
Stage at presentation
 IVA 1 (12)
 IVB 7 (88)
Previous treatment
 Systemic therapya, Median (range) 3.5 (2–10)
 Thymectomyb 7 (88)
 Chest radiation therapy 7 (88)
  1. a Includes: Cisplatin + Doxorubicin + Cyclophosphamide (PAC), PAC + Prednisone, PAC + Belinostat, Cisplatin + Etoposide, Carboplatin + Etoposide, Carboplatin + Paclitaxel, Gemcitabine + Capecitabine, Cisplatin, Paclitaxel, Gemcitabine, Pemetrexed, Sunitinib, Cixutumumab, Milciclib, Octreotide, Amrubicin, Saracatinib, and Belinostat. bIncludes one case of debulking surgery